Etabolic control marker (Table 6). The best cutoff for predicting cardiovascular events (86.6) identified 80 of patients who suffered a cardiovascular event and was associated with a risk of events 10.7 times higher over time. It was lower than the value commonly used to predict high risk of CAD in general population (400). A CS of 0, as a low risk marker, missed one patient with significant CAD
Etabolic control marker (Table 6). The best cutoff for predicting cardiovascular events (86.6) identified 80 of patients who suffered a cardiovascular event and was associated with a risk of events 10.7 times higher over time. It was lower than the value commonly used to predict high risk of CAD in general population (400). A CS of 0, as a low risk marker, missed one patient with significant CAD
Evaluated. Laboratorial tests included total cholesterol, triglycerides, high density lipoprotein cholesterol, low density lipoprotein cholesterol, hemoglobin A1c, serum creatinine, Creactive protein and microalbuminuria. Body mass index, GFR (MDRD formula) and Framingham risk score [17] were calculated. Hypertension and dyslipidemia were defined by a self-reported history or use of specific thera
Ulness of CTA or functional tests in screening asymptomatic diabetics [5,7,8,14]. No study to date has demonstrated additional value of CS and CTA when associated to clinical variables and classic risk scores, such as Framingham. This study aims to assess the additional benefit of CS and CTA, when added to clinical risk stratification schemes, to predict fatal and non fatal cardiovascular events i
Fraction by the heart failure and echocardiography associations of the European society of cardiology. Eur Heart J 2007, 28:2539?550. Devereux RB, Reichek N: Echocardiographic determination of left ventricular mass in man: anatomic validation of the method. Circulation 1977, 55:613?18.25. Pollentier B, Irons SL, Benedetto CM, Dibenedetto AM, Loton D, Seyler RD, et al: Examination of the six minute
The European society of cardiology: developed in collaboration with the heart failure association (HFA) of the ESC. Eur J Heart Fail 2012, 14:803?69. Rose GA, Blackburn H: Cardiovascular survey methods. Geneva: World Health Organisation; 1982. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al: Recommendations for chamber quantification: a report from the American society
The European society of cardiology: developed in collaboration with the heart failure association (HFA) of the ESC. Eur J Heart Fail 2012, 14:803?69. Rose GA, Blackburn H: Cardiovascular survey methods. Geneva: World Health Organisation; 1982. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al: Recommendations for chamber quantification: a report from the American society
Programme): an international survey. Lancet 2002, 360:1631?639. Rutten FH, Grobbee DE, Hoes AW: Differences between general practitioners and cardiologists in diagnosis and management of heart failure: a survey in every-day practice. Eur J Heart Fail 2003, 5:337?44. Rostagno C, Olivo G, Comeglio M, Boddi V, Banchelli M, Galanti G, et al: Prognostic value of 6-minute walk corridor test in patients